Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

1.

Use of hepatotoxic drugs in chronic liver disease.

Hug BL, Surber C, Bates DW.

J Patient Saf. 2012 Jun;8(2):45-50. doi: 10.1097/PTS.0b013e3182482df2. Review.

PMID:
22525363
[PubMed - indexed for MEDLINE]
2.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
[PubMed - indexed for MEDLINE]
3.

[Drug treatment of elderly patients].

Thürmann PA, Schmiedl S.

Med Klin Intensivmed Notfmed. 2011 Sep;106(1):16-23. doi: 10.1007/s00063-011-0041-6. Epub 2011 Oct 7. Review. German.

PMID:
21975837
[PubMed - indexed for MEDLINE]
4.

[Hepatic tolerance of atypical antipsychotic drugs].

Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D.

Encephale. 2002 Nov-Dec;28(6 Pt 1):542-51. Review. French.

PMID:
12506267
[PubMed - indexed for MEDLINE]
5.

Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease.

Hug BL, Lipsitz SR, Seger DL, Karson AS, Wright SC, Bates DW.

Swiss Med Wkly. 2009 Dec 26;139(51-52):737-46. doi: smw-12686.

PMID:
19924579
[PubMed - indexed for MEDLINE]
Free Article
6.

Preoperative assessment of liver function.

Schneider PD.

Surg Clin North Am. 2004 Apr;84(2):355-73. Review.

PMID:
15062650
[PubMed - indexed for MEDLINE]
7.

The Model for End-Stage Liver Disease score: an independent prognostic factor of mortality in injured cirrhotic patients.

Inaba K, Barmparas G, Resnick S, Browder T, Chan LS, Lam L, Talving P, Demetriades D.

Arch Surg. 2011 Sep;146(9):1074-8. doi: 10.1001/archsurg.2011.109. Epub 2011 May 16.

PMID:
21576598
[PubMed - indexed for MEDLINE]
8.

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Verbeeck RK.

Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2. Review.

PMID:
18762933
[PubMed - indexed for MEDLINE]
9.

[Common errors in pharmacotherapy of patients with chronic kidney disease].

Maus S, Keller F.

MMW Fortschr Med. 2011 Apr 21;153(16):39-42. German. No abstract available.

PMID:
22329322
[PubMed - indexed for MEDLINE]
10.

What are barriers to pharmacogenomics (PGx) clinical uptake?

Ieiri I.

Drug Metab Pharmacokinet. 2012;27(3):279. No abstract available.

PMID:
22790064
[PubMed - indexed for MEDLINE]
Free Article
11.

Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.

Otsubo Y, Asahina Y, Noguchi A, Sato Y, Ando Y, Uyama Y.

Drug Metab Pharmacokinet. 2012;27(1):142-9. Epub 2011 Dec 27.

PMID:
22201121
[PubMed - indexed for MEDLINE]
Free Article
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
13.

Drug-induced liver injury in humans: the case of ximelagatran.

Keisu M, Andersson TB.

Handb Exp Pharmacol. 2010;(196):407-18. doi: 10.1007/978-3-642-00663-0_13. Review.

PMID:
20020269
[PubMed - indexed for MEDLINE]
14.

[The deadly sins of pharmacotherapy in chronic kidney disease].

Kielstein JT.

MMW Fortschr Med. 2014 Apr 17;156(7):38-40. German. No abstract available.

PMID:
24956655
[PubMed - indexed for MEDLINE]
15.

[Tuberculosis in compromised hosts].

[No authors listed]

Kekkaku. 2003 Nov;78(11):717-22. Japanese.

PMID:
14672050
[PubMed - indexed for MEDLINE]
16.

Drug use and dosing in chronic kidney disease.

Hassan Y, Al-Ramahi R, Abd Aziz N, Ghazali R.

Ann Acad Med Singapore. 2009 Dec;38(12):1095-103. Review.

PMID:
20052447
[PubMed - indexed for MEDLINE]
Free Article
17.

Management of HBV- and HCV-induced end stage liver disease.

Mutimer DJ, Lok A.

Gut. 2012 May;61 Suppl 1:i59-67. doi: 10.1136/gutjnl-2012-302076. Review.

PMID:
22504920
[PubMed - indexed for MEDLINE]
18.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
[PubMed - indexed for MEDLINE]
19.

A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.

Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM.

Gastroenterology. 2011 Jun;140(7):1952-60. doi: 10.1053/j.gastro.2011.02.017. Epub 2011 Feb 18.

PMID:
21334338
[PubMed - indexed for MEDLINE]
20.

The impact of azathioprine on chronic viral hepatitis in renal transplantation: a long-term, single-center, prospective study on azathioprine withdrawal.

David-Neto E, Americo da Fonseca J, Jota de Paula F, Nahas WC, Sabbaga E, Ianhez LE.

Transplantation. 1999 Oct 15;68(7):976-80.

PMID:
10532537
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk